This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2023 Sep 1;41(25):4183-4184.

doi: 10.1200/JCO.23.01011. Epub 2023 Jun 27.

Reply to C. Springfeld et al

Gulam A Manji¹

Affiliations

Affiliation

¹ Gulam A. Manji, MD, PhD, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY, New York Presbyterian Hospital, Herbert Irving Pavilion, New York, NY, Herbert Irving Comprehensive Cancer Center, New York, NY.

PMID: 37369091
DOI: 10.1200/JCO.23.01011

Comment

Reply to C. Springfeld et al

Gulam A Manji. J Clin Oncol. 2023.

. 2023 Sep 1;41(25):4183-4184.

doi: 10.1200/JCO.23.01011. Epub 2023 Jun 27.

Author

Gulam A Manji¹

Affiliation

¹ Gulam A. Manji, MD, PhD, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY, New York Presbyterian Hospital, Herbert Irving Pavilion, New York, NY, Herbert Irving Comprehensive Cancer Center, New York, NY.

PMID: 37369091
DOI: 10.1200/JCO.23.01011

No abstract available

PubMed Disclaimer

Comment on

Interpreting Primary End Points in Randomized Trials of Pancreatic Cancer.
Springfeld C, Büchler MW, Neoptolemos JP. Springfeld C, et al. J Clin Oncol. 2023 Sep 1;41(25):4182-4183. doi: 10.1200/JCO.23.00779. Epub 2023 Jun 27. J Clin Oncol. 2023. PMID: 37369095 No abstract available.

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.